⌘+K

Pulse Explore Communities Researchers Journals

Home Communities Explore

March 28, 2018The Journal of Infectious DiseasesOpen Access

HIV-1 Resistance Dynamics in Patients With Virologic Failure to Dolutegravir Maintenance Monotherapy

Ingeborg E A Wijting Cynthia Lungu Bart Rijnders Marc van der Valk Hanh Thi Pham Thibault Mésplède Suzan D. Pas Jolanda J.C. Voermans Rob Schuurman David van de Vijver Patrick H. M. Boers Rob A. Gruters Charles A. Boucher Jeroen J. A. van Kampen

View Full Paper

Ask AI

Bookmark

Share

No abstract yet

We only have this paper's title and publication details.

Read it at the source→

Abstract

Nct02401828.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Wijting et al. (2018) studied this question.

synapsesocial.com/papers/69d8403905ee2ba81dbef4fc https://doi.org/10.1093/infdis/jiy176

View Full Paper

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Quantitative evaluation of the antiretroviral efficacy of dolutegravirOriginal Research · 2016 · 15 citations
2Brief ReportRCT · 2015 · 226 citations
3Once‐daily dolutegravir is superior to once‐daily darunavir/ritonavir in treatment‐naïve HIV‐1‐positive individuals: 96 week results from FLAMINGORCT · 2014 · 52 citations
4Dolutegravir versus raltegravir in antiretroviral-experienced, integrase-inhibitor-naive adults with HIV: week 48 results from the randomised, double-blind, non-inferiority SAILING studyRCT · 2013 · 516 citations
5Cross-resistance Profile of the Novel Integrase Inhibitor Dolutegravir (S/GSK1349572) Using Clonal Viral Variants Selected in Patients Failing RaltegravirOriginal Research · 2011 · 97 citations

<i>In Vitro</i>Antiretroviral Properties of S/GSK1349572, a Next-Generation HIV Integrase Inhibitor2010
Development of a phenotypic susceptibility assay for HIV-1 integrase inhibitors2016
Safety and Efficacy of Dolutegravir in Treatment-Experienced Subjects With Raltegravir-Resistant HIV Type 1 Infection: 24-Week Results of the VIKING Study2012
IL-6 Blockade with Clazakizumab is Associated with Low Myeloid Cell Activation and Increased Type 2 Immune Responses in Non-survivors of COVID-19The Journal of Infectious Diseases · 2026
EBV-infected cell lineage by EBER double-staining as a diagnostic and prognostic clue in pediatric EBV-related lymphoproliferative disorders: a Japanese central pathology cohort studyThe Journal of Infectious Diseases · 2026

More from The Journal of Infectious Diseases

More from McGill University

More from Erasmus University Rotterdam

More from Erasmus MC

More from University Medical Center Utrecht

More from Jewish General Hospital